Post-COVID-19-Invasive Pulmonary Mycosis

Abstract

COVID-19 has been associated with myriad manifestations as well as adverse outcomes. One of the less commonly reported consequences of COVID-19 is the occurrence of secondary infections in patients suffering acutely from COVID-19 or in those recuperating. Secondary invasive fungal infections (IFIs) have also been observed earlier in other viral infections such as influenza, parainfluenza, and respiratory syncytial virus infections. Severe lung damage and immunologic derangement resulting from SARS-CoV-2 infection predispose to superinfections. Risk factors for secondary IFI includes immunologic derangement and immunoparalysis resulting from SARS-CoV-2 infection, neutropenia, or lymphopenia, poorly controlled diabetes, structural lung disease fungal colonization, and drugs such as corticosteroids or immunomodulators given as therapies for COVID-19. Invasive aspergillosis following COVID-19 is most commonly described fungal infection but other non-Aspergillus fungal infections (including mucormycosis) has also been reported. Herein we describe two interesting cases of secondary infections developing in patients beyond the acute phase of COVID-19 who had similar presentations but with different diagnoses and requiring different management strategies. Patient in case 1 developed COVID-19-associated subacute invasive pulmonary aspergillosis (SAIA) and patient in case 2 had COVID-19 associated pulmonary mucormycosis (CAPM). We have also described the various postulated immune-pathogenesis of the super-added fungal infections in COVID-19 patients.

Keywords

COVID-19 - mucorales - aspergillosis - immune dysfunction

Consent

Consent was obtained from the patient directly.

Ethics Approval

Not required (as being a case report).

Authors' Contributions

SS, AR: conceptualization; SS, KS, AR, MJ: involved in patient management. All authors contributed to drafting the initial manuscript. Manuscript was proofread and reviewed by SS and NW.

Publikationsverlauf

Artikel online veröffentlicht:
02. August 2022

• References

• 1 Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity - Machado - 2021 - Mycoses - Wiley Online Library [Internet]. [cited 2021 Oct 30]. Available at: https://onlinelibrary.wiley.com/doi/full/10.1111/myc.13213
• 2 Swain S, Ray A, Sarda R. et al. COVID-19-associated subacute invasive pulmonary aspergillosis. Mycoses [Internet]. [cited 2021 Oct 10];n/a(n/a). Available at: https://onlinelibrary.wiley.com/doi/abs/10.1111/myc.13369
• 3 Binder RE, Faling LJ, Pugatch RD, Mahasaen C, Snider GL. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore) 1982; 61 (02) 109-124
• 4 Kim SY, Lee KS, Han J. et al. Semiinvasive pulmonary aspergillosis: CT and pathologic findings in six patients. Am J Roentgenol 2000; 174 (03) 795-798
• 5 Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management | European Respiratory Society [Internet]. [cited 2021 Jul 16]. Available at: https://erj.ersjournals.com/content/47/1/45
• 6 Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol 2018; 56 (Suppl. 01) 93-101
• 7 Narayanan S, Chua JV, Baddley JW. Coronavirus disease 2019–associated mucormycosis: risk factors and mechanisms of disease. Clin Infect Dis 2022; 74 (07) 1279-1283
• 8 Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020; 20 (06) 363-374
• 9 Ray A, Goel A, Wig N. Corticosteroids for treating mild COVID-19: opening the floodgates of therapeutic misadventure. QJM 2021; 114 (08) 541-542
• 10 Pal R, Singh B, Bhadada SK. et al. COVID-19-associated mucormycosis: an updated systematic review of literature. Mycoses [Internet]. [cited 2021 Sep 23];n/a(n/a). Available at: https://onlinelibrary.wiley.com/doi/abs/10.1111/myc.13338
• 11 Baldin C, Ibrahim AS. Molecular mechanisms of mucormycosis-the bitter and the sweet. PLoS Pathog 2017; 13 (08) e1006408
• 12 Sarda R, Swain S, Ray A, Wig N. COVID-19-associated mucormycosis: an epidemic within a pandemic. QJM 2021; 114 (06) 355-356
• 13 Garg M, Prabhakar N, Muthu V. et al. CT findings of COVID-19–associated pulmonary mucormycosis: a case series and literature review. Radiology 2022; 302 (01) 214-217
• 14 Marty FM, Ostrosky-Zeichner L, Cornely OA. et al; VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 2016; 16 (07) 828-837
• 15 Cornely OA, Alastruey-Izquierdo A, Arenz D. et al; Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19 (12) e405-e421